The Asia Pacific radiopharmaceutical theranostics market was valued at US$ 337.53 million in 2022 and is expected to reach US$ 667.40 million by 2028; it is estimated to register a CAGR of 12.0% from 2022 to 2028.
Based on radioisotope, the Asia Pacific radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the Asia Pacific radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the Asia Pacific radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and Companion Diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in 2022.
Based on indication, the Asia Pacific radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the Asia Pacific radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The oncology segment held the largest market share in 2022.
Based on country, the Asia Pacific radiopharmaceutical theranostics market is segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific radiopharmaceutical theranostics market share in 2022.
Bayer AG, GE Healthcare Technologies Inc., Curium, Telix Pharmaceuticals Ltd., and Cardinal Health Inc. are among the leading companies operating in the Asia Pacific radiopharmaceutical theranostics market.
Radiopharmaceutical Theranostics in Nuclear Medicine
Theranostics in nuclear medicine gathers researchers’ interest through molecular imaging and personalized medicine. This is achieved through assistance in the management of various diseases, improves patient selection process, predicts drug response and toxicity, determines prognosis, and helps avoid futile and costly/expensive examinations and treatments. The theranostic approach to nuclear medicine involves a combination of diagnostic imaging and therapy based on a radioactive drug; its primary focus is the diagnosis, while the secondary focus is the treatment of a tumor site. Radioiodine was the first theranostic radiopharmaceutical used in treating and imaging thyroid diseases. In radioiodine therapy, the radioisotope iodine-131 is a gamma and beta emitter, and the sodium-iodide symporter can directly mediate the gamma emitter to thyroid cells. Further, gamma and positron emitters (β+) are used in nuclear imaging. Gamma emitters such as technetium-99m or iodine-123 are used in SPECT imaging, whereas the use of gallium-68 and fluorine-18 in PET imaging can provide better resolution. Therefore, theranostics-based nuclear-targeted therapies are emerging as a useful tool for treating patients suffering from advanced neuroendocrine and gastroenteropancreatic tumors such as neuroblastomas.Asia Pacific Radiopharmaceutical Theranostics Market Overview
The Asia Pacific radiopharmaceutical theranostics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China held the largest share of the market in 2021, and India is expected to exhibit a significant growth pace in the market during the forecast period. The market growth in these countries is attributed to the rising chronic disease prevalence and favorable reimbursement policies. Moreover, expansion and product launch strategies implemented by market players are expected to contribute to the growth of the radiopharmaceutical theranostics market in the region.Asia Pacific Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Radiopharmaceutical Theranostics Market Segmentation
The Asia Pacific radiopharmaceutical theranostics market is segmented into product type, radioisotope, source, application, indication, end user, and country. Based on product type, the Asia Pacific radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and positron emission tomography (PET) tracers. The PET tracers segment held the largest market share in 2022.Based on radioisotope, the Asia Pacific radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the Asia Pacific radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the Asia Pacific radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and Companion Diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in 2022.
Based on indication, the Asia Pacific radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the Asia Pacific radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The oncology segment held the largest market share in 2022.
Based on country, the Asia Pacific radiopharmaceutical theranostics market is segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific radiopharmaceutical theranostics market share in 2022.
Bayer AG, GE Healthcare Technologies Inc., Curium, Telix Pharmaceuticals Ltd., and Cardinal Health Inc. are among the leading companies operating in the Asia Pacific radiopharmaceutical theranostics market.
Table of Contents
1. Introduction
3. Research Methodology
4. Asia Pacific Radiopharmaceutical Theranostics Market - Market Landscape
5. Asia Pacific Radiopharmaceutical Theranostics Market - Key Market Dynamics
6. Radiopharmaceutical Theranostics Market - Asia Pacific Analysis
7. Asia Pacific Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type
8. Asia Pacific Radiopharmaceutical Theranostics Market Analysis - by Radioisotope
9. Asia Pacific Radiopharmaceutical Theranostics Market Analysis - by Source
10. Asia Pacific Radiopharmaceutical Theranostics Market Analysis - by Application
11. Asia Pacific Radiopharmaceutical Theranostics Market Analysis - by Indication
12. Asia Pacific Radiopharmaceutical Theranostics Market Analysis - by End User
13. Asia Pacific Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Country Analysis
14. Radiopharmaceutical Theranostics Market - Industry Landscape
15. Company Profiles
16. Appendix
List of Tables
List of Figure
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- GE Healthcare Technologies Inc.
- Curium
- Telix Pharmaceuticals Ltd.
- Cardinal Health Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 184 |
| Published | June 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 337.53 million |
| Forecasted Market Value ( USD | $ 667.4 million |
| Compound Annual Growth Rate | 12.0% |
| Regions Covered | Asia Pacific |
